209 related articles for article (PubMed ID: 21053358)
1. Nonmelanoma skin cancer in inflammatory bowel disease: a review.
Long MD; Kappelman MD; Pipkin CA
Inflamm Bowel Dis; 2011 Jun; 17(6):1423-7. PubMed ID: 21053358
[TBL] [Abstract][Full Text] [Related]
2. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
3. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
4. Risk of nonmelanoma skin cancer with azathioprine use.
Maddox JS; Soltani K
Inflamm Bowel Dis; 2008 Oct; 14(10):1425-31. PubMed ID: 18383175
[TBL] [Abstract][Full Text] [Related]
5. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
Hagen JW; Pugliano-Mauro MA
Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
[TBL] [Abstract][Full Text] [Related]
6. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
[TBL] [Abstract][Full Text] [Related]
7. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
8. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
[TBL] [Abstract][Full Text] [Related]
9. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.
Ariyaratnam J; Subramanian V
Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
Singh H; Nugent Z; Demers AA; Bernstein CN
Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
[TBL] [Abstract][Full Text] [Related]
11. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
Huang SZ; Liu ZC; Liao WX; Wei JX; Huang XW; Yang C; Xia YH; Li L; Ye C; Dai SX
J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
[TBL] [Abstract][Full Text] [Related]
12. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.
Townsend CM; Khanna R; Wilson AS
Dig Dis Sci; 2021 Dec; 66(12):4436-4440. PubMed ID: 33428042
[TBL] [Abstract][Full Text] [Related]
13. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database.
Saliba L; Moulis G; Abou Taam M; Rousseau V; Chebane L; Petitpain N; Baldin B; Pugnet G; Montastruc JL; Bagheri H
Fundam Clin Pharmacol; 2016 Apr; 30(2):162-71. PubMed ID: 26604187
[TBL] [Abstract][Full Text] [Related]
15. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?
Bebb JR; Logan RP
Aliment Pharmacol Ther; 2001 Dec; 15(12):1843-9. PubMed ID: 11736713
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease].
Kim JH; Kim JW
Korean J Gastroenterol; 2017 Oct; 70(4):162-168. PubMed ID: 29060953
[TBL] [Abstract][Full Text] [Related]
17. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management.
Tessari G; Girolomoni G
Dermatol Surg; 2012 Oct; 38(10):1622-30. PubMed ID: 22805312
[TBL] [Abstract][Full Text] [Related]
18. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
19. Abnormal Pap smears in inflammatory bowel disease.
Kane S
Inflamm Bowel Dis; 2008 Aug; 14(8):1158-60. PubMed ID: 18266234
[TBL] [Abstract][Full Text] [Related]
20. Skin changes following organ transplantation: an interdisciplinary challenge.
Ulrich C; Arnold R; Frei U; Hetzer R; Neuhaus P; Stockfleth E
Dtsch Arztebl Int; 2014 Mar; 111(11):188-94. PubMed ID: 24698074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
